Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
27 Jun 24
8-K
Entry into a Material Definitive Agreement
7 May 24
424B3
Prospectus supplement
7 May 24
424B5
Prospectus supplement for primary offering
7 May 24
S-3ASR
Automatic shelf registration
7 May 24
10-Q
2024 Q1
Quarterly report
7 May 24
8-K
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
7 May 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
8-K
Other Events
2 Apr 24
8-K
Entry into a Material Definitive Agreement
20 Mar 24
424B5
Prospectus supplement for primary offering
20 Mar 24
424B5
Prospectus supplement for primary offering
18 Mar 24
8-K
Regulation FD Disclosure
14 Mar 24
8-K
Departure of Directors or Certain Officers
28 Feb 24
8-K
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
UPLOAD
Letter from SEC
25 Jan 24
CORRESP
Correspondence with SEC
17 Jan 24
8-K
Other Events
8 Jan 24
UPLOAD
Letter from SEC
3 Jan 24
CORRESP
Correspondence with SEC
14 Dec 23
CORRESP
Correspondence with SEC
8 Dec 23
UPLOAD
Letter from SEC
21 Nov 23
8-K
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023
6 Nov 23
10-Q
2023 Q3
Quarterly report
6 Nov 23
8-K
Entry into a Material Definitive Agreement
2 Oct 23
424B5
Prospectus supplement for primary offering
2 Oct 23
424B5
Prospectus supplement for primary offering
28 Sep 23
8-K
Departure of Directors or Certain Officers
25 Sep 23
8-K
Departure of Directors or Certain Officers
14 Sep 23
8-K
Departure of Directors or Certain Officers
13 Sep 23
8-K
Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug
13 Sep 23
S-8
Registration of securities for employees
11 Sep 23
424B3
Prospectus supplement
8 Aug 23
8-K
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results
8 Aug 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Other Events
17 Jul 23
8-K
Madrigal expects to complete full submission of the New Drug Application in July 2023
30 Jun 23
Latest ownership filings
4
FRED B CRAVES
27 Jun 24
4
KENNETH BATE
27 Jun 24
4
James M Daly
27 Jun 24
4
Richard S Levy
27 Jun 24
4
PAUL A FRIEDMAN
27 Jun 24
4
JULIAN BAKER
27 Jun 24
4
Robert E. Waltermire
18 Jun 24
4
Robert E. Waltermire
14 Jun 24
144
Notice of proposed sale of securities
14 Jun 24
144
Notice of proposed sale of securities
14 Jun 24
4
FRED B CRAVES
13 Jun 24
144
Notice of proposed sale of securities
13 Jun 24
144
Notice of proposed sale of securities
12 Jun 24
144
Notice of proposed sale of securities
11 Jun 24
144
Notice of proposed sale of securities
6 Jun 24
4
Robert E. Waltermire
23 May 24
4
FRED B CRAVES
16 May 24
144
Notice of proposed sale of securities
14 May 24
4
Rebecca Taub
10 Apr 24
4
PAUL A FRIEDMAN
10 Apr 24
4
Rebecca Taub
5 Apr 24
4
PAUL A FRIEDMAN
5 Apr 24
4
Richard S Levy
3 Apr 24
4
KENNETH BATE
3 Apr 24
4
James M Daly
3 Apr 24
144
Notice of proposed sale of securities
3 Apr 24
144
Notice of proposed sale of securities
3 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
SC 13D/A
BAKER BROS. ADVISORS LP
25 Mar 24
4
Change in insider ownership
25 Mar 24
3
Mardi Dier
21 Mar 24
SC 13G/A
PAULSON & CO. INC.
14 Feb 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
Avoro Capital Advisors LLC
14 Feb 24
SC 13G/A
JANUS HENDERSON GROUP PLC
13 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
BlackRock Inc.
29 Jan 24
4
Carole Huntsman
25 Jan 24